Acelyrin, Poison Pill and Tang Capital
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...
The Rights Plan is effective immediately and will expire on March 12, 2026. ACELYRIN stockholders do not need to take any further action at this time.
But a curveball from Concentra could change all that. The Tang Capital Partners-owned biotech has offered to buy all outstanding shares of Acelyrin for $3 per share in cash, along with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback